ArticleFrontiers in endocrinology2025
Association of hemoglobin-to-red cell distribution width ratio with diabetic retinopathy risk and severity.
Article in Frontiers in endocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Diabetic retinopathy (DR) is a leading cause of blindness in diabetic patients, driven by inflammation, oxidative stress, and hypoxia. The hemoglobin-to-red cell distribution width ratio (HRR) is a novel inflammatory marker reflecting these pathological mechanisms. This study aimed to investigated the association of HRR with DR risk and severity. Methods: Data from the 2005-2008 National Health and Nutrition Examination Survey were analyzed using weighted logistic regression, subgroup analysis, restricted cubic splines, mediation analysis, and other methods. Results: Among 1,260 diabetic patients, HRR was inversely associated with DR development (OR = 0.85, P = 0.008), remaining significant post-propensity score matching. A non-linear relationship was identified, with an inflection point at HRR = 10.81 (P for non-linearity < 0.001), above which the protective effect strengthened with increasing HRR. Mediation analyses revealed diastolic blood pressure (15.9% mediation) and HbA1c (60.5% competitive mediation) as partial mediators of the HRR-DR association. HRR was also inversely associated with DR severity, particularly proliferative DR (vs. mild non-proliferative DR: OR = 0.67, P = 0.030; vs. severe non-proliferative DR: OR = 0.04, P = 0.002). Conclusions: HRR is negatively correlated with DR onset and progression, highlighting its potential as a cost-effective biomarker for DR risk stratification.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.